Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis

被引：1
|
作者：
Wendling, Daniel [1 ]
Goupille, Philippe [2 ]
机构：
[1] Univ Franche Comte, CHRU Besancon, Serv Rhumatol, EA 4266, Besancon, France
[2] Univ Tours, CHRU Tours, Serv Rhumatol, EA 7501,GICC, Tours, France
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 12期
关键词：
ankylosing spondylitis; anti-IL-17; anti-TNF; axial spondyloarthritis; disease activity; treatment; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0094
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：857 / 860
页数：4
相关论文
共 50 条
  • [31] Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR
    Kedra, Joanna
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    JOINT BONE SPINE, 2021, 88 (01)
  • [32] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [33] The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
    Goralczyk, Alicja
    Kolossa, Katarzyna
    Waszczak-Jeka, Marzena
    Adamczak, Rafal
    Jeka, Slawomir
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 306 - 312
  • [34] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [35] Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis
    Wang, Runsheng
    Bathon, Joan M.
    Ward, Michael M.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (04) : 518 - 528
  • [36] Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement
    Simone, Davide
    Nowik, Marcin
    Gremese, Elisa
    Ferraccioli, Gianfranco F.
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 65 - 69
  • [37] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano
    Behlouli, Hassan
    Curtis, Jeffrey
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 937 - 938
  • [38] COMPARATIVE EFFECTIVENESS OF TOFACITINIB, BIOLOGIC DRUGS AND TRADITIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Moura, C. S.
    Machado, M. A.
    Behlouli, H.
    Curtis, J. R.
    Abrahamowicz, M.
    Bernatsky, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 825 - 826
  • [39] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano S.
    Behlouli, Hassan
    Curtis, Jeffiey R.
    Bernatsky, Sasha
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] Combinations of conventional disease-modifying antirheumatic drugs
    O'Dell, JR
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (02) : 415 - 426
12345